These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33727309)

  • 1. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome.
    Liudahl SM; Betts CB; Sivagnanam S; Morales-Oyarvide V; da Silva A; Yuan C; Hwang S; Grossblatt-Wait A; Leis KR; Larson W; Lavoie MB; Robinson P; Dias Costa A; Väyrynen SA; Clancy TE; Rubinson DA; Link J; Keith D; Horton W; Tempero MA; Vonderheide RH; Jaffee EM; Sheppard B; Goecks J; Sears RC; Park BS; Mori M; Nowak JA; Wolpin BM; Coussens LM
    Cancer Discov; 2021 Aug; 11(8):2014-2031. PubMed ID: 33727309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.
    Gartrell RD; Enzler T; Kim PS; Fullerton BT; Fazlollahi L; Chen AX; Minns HE; Perni S; Weisberg SP; Rizk EM; Wang S; Oh EJ; Guo XV; Chiuzan C; Manji GA; Bates SE; Chabot J; Schrope B; Kluger M; Emond J; Rabadán R; Farber D; Remotti HE; Horowitz DP; Saenger YM
    Oncoimmunology; 2022; 11(1):2066767. PubMed ID: 35558160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling pancreatic cancer in mice for experimental therapeutics.
    Mallya K; Gautam SK; Aithal A; Batra SK; Jain M
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188554. PubMed ID: 33945847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers.
    Mi H; Sivagnanam S; Betts CB; Liudahl SM; Jaffee EM; Coussens LM; Popel AS
    Cancer Res; 2022 Dec; 82(23):4359-4372. PubMed ID: 36112643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma - Heading towards a promising change in treatment paradigm.
    Mahmood U; Carrier E; Khan K
    Cancer Treat Rev; 2024 Jun; 127():102750. PubMed ID: 38703592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer.
    Yousuf S; Qiu M; Voith von Voithenberg L; Hulkkonen J; Macinkovic I; Schulz AR; Hartmann D; Mueller F; Mijatovic M; Ibberson D; AlHalabi KT; Hetzer J; Anders S; Brüne B; Mei HE; Imbusch CD; Brors B; Heikenwälder M; Gaida MM; Büchler MW; Weigert A; Hackert T; Roth S
    Gastroenterology; 2023 Oct; 165(4):891-908.e14. PubMed ID: 37263303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model.
    Shafiekhani S; Dehghanbanadaki H; Fatemi AS; Rahbar S; Hadjati J; Jafari AH
    BMC Cancer; 2021 Nov; 21(1):1226. PubMed ID: 34781899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes.
    de Koning W; Latifi D; Li Y; van Eijck CHJ; Stubbs AP; Mustafa DAM
    Front Immunol; 2021; 12():649061. PubMed ID: 33986743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
    Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
    Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer.
    Blise KE; Sivagnanam S; Betts CB; Betre K; Kirchberger N; Tate BJ; Furth EE; Dias Costa A; Nowak JA; Wolpin BM; Vonderheide RH; Goecks J; Coussens LM; Byrne KT
    Cancer Immunol Res; 2024 May; 12(5):544-558. PubMed ID: 38381401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.
    Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M
    Front Immunol; 2024; 15():1378190. PubMed ID: 38629072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma.
    Gautam SK; Batra SK; Jain M
    Mol Cancer; 2023 Jul; 22(1):118. PubMed ID: 37488598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
    Yu Y; Schuck K; Friess H; Kong B
    Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreas cancer: Therapeutic trials in metastatic disease.
    Smithy JW; O'Reilly EM
    J Surg Oncol; 2021 May; 123(6):1475-1488. PubMed ID: 33831245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.